Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.
暂无分享，去创建一个
J. Leonard | I. Flinn | K. Rai | T. Jahn | S. Coutre | R. Furman | N. Wagner-Johnston | N. Fowler | J. Sharman | J. Barrientos | M. Schreeder | S. Vos | T. Boyd | L. Holes | D. Johnson | R. Dansey | Daniel Li | Leanne Holes